Get the Stockscreener App
10.87
0.91%
-0.10
After Hours:
10.80
-0.07
-0.64%
Roivant Sciences Ltd stock is traded at $10.87, with a volume of 4.85M.
It is down -0.91% in the last 24 hours and down -5.56% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$10.97
Open:
$11.01
24h Volume:
4.85M
Relative Volume:
1.07
Market Cap:
$7.91B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.9239
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-4.40%
1M Performance:
-5.56%
6M Performance:
+5.23%
1Y Performance:
+5.53%
1-Day Range:
$10.84
$11.03
1-Week Range:
$10.65
$11.48
52-Week Range:
$9.76
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.87 | 7.91B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences (ROIV) to Release Earnings on Monday - MarketBeat
DAVENPORT & Co LLC Has $1.89 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Upgraded at Cantor Fitzgerald - Defense World
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching - MarketBeat
Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Roivant sciences president Eric Venker sells $1.13 million in shares - MSN
Zweig DiMenna Associates LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,128,000.00 in Stock - MarketBeat
Why Is Andreas Halvorsen Bullish On Roivant Sciences Ltd. (ROIV) Now? - Yahoo Finance
How Rich Is This Indian-Origin Entrepreneur Who Took On Donald Trump But Is Now…? Check His Net Worth - News24
What Is Vivek Ramaswamy’s net worth? The Indian American man who took on Trump and then became a confidante - The Financial Express
Trump Inauguration: Who Is Vivek Ramaswamy and what’s his role in Trump 2.0? - The Financial Express
Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. Trade Ideas — LS:A3C4MS - TradingView
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com India
Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by JPMorgan Chase & Co. - Defense World
Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIVWroivw Latest Stock News & Market Updates - StockTitan
ROIV Crosses Below Key Moving Average Level - Nasdaq
Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies - MSN
Why Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US Students - The Times of India
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance
10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat
Roivant Sciences' president sells common shares worth $4.1 million - Investing.com India
Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India
Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat
Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):